Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 302

1.

Kit expression in small cell carcinomas of the lung: effects of chemotherapy.

Rossi G, Cavazza A, Marchioni A, Migaldi M, Bavieri M, Facciolongo N, Petruzzelli S, Longo L, Tamberi S, Crinò L.

Mod Pathol. 2003 Oct;16(10):1041-7.

2.

Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung.

Araki K, Ishii G, Yokose T, Nagai K, Funai K, Kodama K, Nishiwaki Y, Ochiai A.

Lung Cancer. 2003 May;40(2):173-80.

PMID:
12711118
3.

Analysis of protein expression and gene mutation of c-kit in colorectal neuroendocrine carcinomas.

Akintola-Ogunremi O, Pfeifer JD, Tan BR, Yan Y, Zhu X, Hart J, Goldblum JR, Burgart L, Lauwers GY, Montgomery E, Lewin D, Washington K, Bronner M, Xiao SY, Greenson JK, Lamps L, Lazenby A, Wang HL.

Am J Surg Pathol. 2003 Dec;27(12):1551-8.

PMID:
14657715
4.

CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients.

Pelosi G, Barisella M, Pasini F, Leon ME, Veronesi G, Spaggiari L, Fraggetta F, Iannucci A, Masullo M, Sonzogni A, Maffini F, Viale G.

Mod Pathol. 2004 Jun;17(6):711-21.

5.

Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.

Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, Bigiani N, Schirosi L, Casali C, Morandi U, Facciolongo N, Maiorana A, Bavieri M, Fabbri LM, Brambilla E.

J Clin Oncol. 2005 Dec 1;23(34):8774-85.

PMID:
16314638
6.

The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung.

Casali C, Stefani A, Rossi G, Migaldi M, Bettelli S, Parise A, Morandi U.

Ann Thorac Surg. 2004 Jan;77(1):247-52; discussion 252-3.

PMID:
14726070
8.

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.

Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, Kris MG, Pizzo B, Tyson L, Dunne M, Heelan RT.

Cancer. 2005 May 15;103(10):2128-31.

9.

Analysis of c-kit expression in small cell lung cancer: prevalence and prognostic implications.

Camps C, Sirera R, Bremnes RM, Garde J, Safont MJ, Blasco A, Berrocal A, Sánchez JJ, Calabuig C, Martorell M.

Lung Cancer. 2006 Jun;52(3):343-7. Epub 2006 Mar 30.

PMID:
16574270
10.

Phase II study of imatinib in patients with small cell lung cancer.

Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski MO, Sayles D, Dimitrijevic S, Fletcher C, Hornick J, Salgia R, Le Chevalier T.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5880-7.

11.

Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers.

Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yamashiro K, Dosaka-Akita H, Nishimura M.

Cancer Sci. 2003 Apr;94(4):394-9.

12.

Enhanced expression of metallothionein in human non-small-cell lung carcinomas following chemotherapy.

Matsumoto Y, Oka M, Sakamoto A, Narasaki F, Fukuda M, Takatani H, Terashi K, Ikeda K, Tsurutani J, Nagashima S, Soda H, Kohno S.

Anticancer Res. 1997 Sep-Oct;17(5B):3777-80.

PMID:
9427779
13.

Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications.

Micke P, Basrai M, Faldum A, Bittinger F, Rönnstrand L, Blaukat A, Beeh KM, Oesch F, Fischer B, Buhl R, Hengstler JG.

Clin Cancer Res. 2003 Jan;9(1):188-94.

14.

Cisplatin-based chemotherapy for postoperative recurrence in non-small cell lung cancer patients: relation of the in vitro chemosensitive test to clinical response.

Higashiyama M, Kodama K, Yokouchi H, Takami K, Nakagawa H, Imamura F, Minamigawa K, Kobayashi H.

Oncol Rep. 2001 Mar-Apr;8(2):279-83.

PMID:
11182040
15.

Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.

Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R, Ulm K, Hessler S, Gatzemeier U.

Lung Cancer. 2006 Jul;53(1):67-75. Epub 2006 May 19.

PMID:
16713013
16.
17.

Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis.

Naeem M, Dahiya M, Clark JI, Creech SD, Alkan S.

Hum Pathol. 2002 Dec;33(12):1182-7.

PMID:
12514786
18.
19.

C-kit overexpression in neuroendocrine small cell carcinoma of the uterine cervix.

Ohwada M, Wada T, Saga Y, Tsunoda S, Jobo T, Kuramoto H, Konno R, Suzuki M.

Eur J Gynaecol Oncol. 2006;27(1):53-5.

PMID:
16550970
20.

[Chemotherapy in extended small-cell lung cancer. Retrospective analysis of two different series of patients treated with carboplatin and etoposide or ciclophosphamide-epidoxorubicin and etoposide].

Tassinari D, Genestreti G, Pasquini E, Fantini M, Poggi B, Tamburini E, Papi M, Ioli G, Oliverio G, Fochessati F, Arcangeli V, Agostini V, Mianulli AM, Imola M, Fattori PP, Ravaioli A.

Recenti Prog Med. 2005 May;96(5):234-9. Italian.

PMID:
15977652

Supplemental Content

Support Center